Írisz K. Kovács

Disulfide rebridging platforms for site-specific ADC conjugation

Antibody–drug conjugates (ADCs) have emerged as a transformative class of targeted therapeutics, combining the exquisite specificity of monoclonal antibodies with the potency of small-molecule cytotoxic payloads. While numerous strategies exist to generate ADCs, site-specific conjugation methods have gained prominence...